Turning Point Brands Raises Guidance, But Margins Lag

Forward-Looking Analysis

Wall Street consensus projects Turning Point Brands’ 2026 revenue to reach $480.9 million, reflecting a robust 19.88% growth rate that significantly outpaces the US Tobacco industry’s average of 3.96% and the broader US market’s 13.86%. Analysts forecast annual earnings of approximately $55.4 million for 2026, with a consensus EPS estimate of $2.16, representing a potential 27.71% decline from current levels but still maintaining positive growth momentum. The single analyst covering the stock maintains a "Buy" rating with a $125 price target, implying a 41.48% upside from recent trading levels. However, quant models rate TPB as a "Strong Sell," citing historical average returns of -8.02% for such ratings. Revenue is forecast to expand to $601.5 million by 2027 and $908 million by 2028, driven by strategic investments in modern oral products. Despite strong revenue growth forecasts, earnings growth is expected to lag behind industry peers at 3.97% versus the industry's 11.61%, indicating margin compression or increased operational costs associated with scaling new product lines.

Historical Performance Review

Turning Point Brands delivered mixed results in its 2026Q1 report, posting total consolidated net sales of $124.28 million, a 16.8% year-over-year increase. Gross profit expanded 14.6% to $68.30 million, supported by strong demand in the Stoker’s segment. However, net income decreased 19.0% to $13.94 million, and diluted EPS fell to $0.61 from $0.81 in the prior year period. The decline in profitability was primarily attributed to increased selling, general, and administrative expenses driven by heavy investments in sales and marketing for its Modern Oral business, which now accounts for 42% of total net sales. Despite lower net income, the company maintained strong liquidity with $192.4 million in cash.

Additional News

Turning Point Brands recently announced the raising of its Full Year 2026 Modern Oral Sales guidance, increasing the net sales forecast to $210-$225 million from the previous range of $180-$190 million. The company also introduced Full Year 2026 Adjusted EBITDA guidance of $70-$90 million. In Q1 2026, Modern Oral net sales surged 133% to $52.0 million, capturing 42% of total company net sales compared to 21% in Q1 2025. The Stoker’s segment saw net sales increase 48.1%, driven by triple-digit growth in Modern Oral products. Conversely, the Zig-Zag segment experienced a 22.4% decline in net sales due to lower U.S. papers and wraps shipments. The company highlighted its partnership with UFC’s TKO as a key initiative to capture share in the white pouch market. Management emphasized disciplined execution and continued investment in brand building and commercial capabilities to support the generational shift in nicotine consumption.

Summary & Outlook

Turning Point Brands exhibits strong top-line growth driven by the rapid expansion of its Modern Oral business, which now constitutes a significant portion of revenue. However, near-term profitability faces pressure from elevated SG&A expenses related to marketing and distribution investments. The company maintains a solid balance sheet with substantial liquidity, supporting its strategic initiatives. While revenue growth forecasts are impressive, earnings growth is expected to underperform peers due to current investment cycles. The stock presents a high-growth narrative with near-term margin headwinds. Given the strong revenue trajectory and successful pivot to modern oral products, the outlook is cautiously bullish, though investors should monitor margin expansion in subsequent quarters to validate the increased guidance.